GSK plc vs MannKind Corporation: SG&A Expense Trends

SG&A Expense Trends: A Tale of Two Companies

In the ever-evolving pharmaceutical landscape, GSK plc and MannKind Corporation present a fascinating study in contrasts. Over the past decade, GSK's Selling, General, and Administrative (SG&A) expenses have shown a steady upward trajectory, peaking in 2020 with a 39% increase from 2014. This reflects GSK's expansive global operations and strategic investments in marketing and administration.

Conversely, MannKind Corporation, a smaller player, has maintained a more volatile SG&A expense pattern, with fluctuations reflecting its adaptive strategies in a competitive market. Notably, MannKind's expenses in 2023 were approximately 19% higher than in 2014, indicating a cautious yet progressive approach.

This comparison underscores the diverse strategies employed by pharmaceutical giants and emerging companies alike, highlighting the balance between growth and fiscal prudence in the industry.